Coagulation Factor Concentrates Market by Product Type (Plasma Derived, Recombinant), Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease), Formulation, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Coagulation Factor Concentrates Market was valued at USD 8.84 billion in 2024 and is projected to grow to USD 9.59 billion in 2025, with a CAGR of 8.62%, reaching USD 17.14 billion by 2032.
Providing a clear contextual foundation for current clinical, regulatory, and commercial dynamics shaping coagulation factor concentrates across care settings
Coagulation factor concentrates remain central to the management of inherited bleeding disorders and acquired coagulopathies, shaping care pathways across hospitals and specialty treatment centers. Over the past decade, therapeutic sophistication has increased as recombinant engineering and product formulation advances improved safety profiles and dosing convenience. These clinical improvements occur alongside evolving health system expectations for cost containment, supply reliability, and demonstrable patient outcomes, which together influence purchasing decisions and treatment protocols.
Clinicians and health systems now balance efficacy with practical considerations such as storage, administration logistics, and continuity of supply. Meanwhile, regulatory frameworks are maturing to accommodate novel biologics, accelerated approvals, and post-marketing surveillance demands. As a result, stakeholders from manufacturers to payers and providers must navigate a complex environment where clinical evidence, manufacturing capacity, and health-economic justification intersect. This introduction frames the broader commercial and clinical context for deeper strategic analysis and highlights why a disciplined, evidence-driven response is essential for sustained competitiveness.
Analyzing the multifaceted technological, regulatory, and operational shifts reshaping product development, supply chains, and care pathways in coagulation therapies
The landscape for coagulation factor concentrates is undergoing transformative shifts that are redefining competitive advantage and patient pathways. Recombinant biologics with improved half-life properties have altered treatment cadence and adherence patterns, while formulation innovations such as ready-to-use liquid and stable lyophilized presentations have reduced administration burdens in acute and chronic care settings. Concurrently, digital therapeutics and remote monitoring are beginning to complement infusion programs, enabling more precise dosing and improved safety surveillance.
Supply chain resiliency and manufacturing decentralization are gaining priority as stakeholders seek to mitigate disruption risks and meet localized demand. Regulatory convergence on quality and traceability has increased expectations for post-market evidence generation and cold-chain integrity. Moreover, evolving reimbursement frameworks now place greater emphasis on value-based outcomes, prompting manufacturers to invest in real-world evidence and patient support services. Taken together, these shifts require companies to integrate clinical innovation with operational agility and evidence generation to secure long-term market relevance.
Assessing the broad operational, procurement, and strategic consequences resulting from United States tariff policy changes and their downstream effects on global supply dynamics
The introduction of new tariff measures in the United States in 2025 has created a cascade of operational and strategic responses across global suppliers and domestic purchasers of coagulation factor concentrates. Increased import-related costs have prompted manufacturers to reassess global production footprints and accelerate plans for local manufacturing or contract manufacturing organization partnerships to protect margin and continuity of supply. For institutional buyers, procurement teams are recalibrating tender specifications and supplier qualification criteria to reflect shifting landed costs and to preserve access for vulnerable patient populations.
In response, companies are employing hedging strategies, renegotiating long-term supply agreements, and exploring localized inventory buffers to reduce exposure to tariff volatility. Meanwhile, regulatory and market access teams are prioritized to expedite alternate sourcing approvals and to align labeling and quality documentation across jurisdictions. These adaptations are fostering greater collaboration between commercial, legal, and manufacturing functions within organizations. Importantly, the tariff-driven environment also incentivizes innovation in logistics, including consolidated shipping, optimized cold-chain strategies, and strategic warehousing, all aimed at sustaining patient access while containing operational complexity.
Delivering granular strategic insights across product type, clinical indication, formulation, end user, distribution channels, and administration route to inform targeted commercialization
A nuanced segmentation analysis highlights differentiated commercial and clinical imperatives across product types, indications, formulations, end users, distribution channels, and administration routes. Within product type, plasma-derived offerings continue to play a critical role where established safety records and donor-derived attributes are prioritized, while recombinant products-split between extended half-life and standard half-life variants-drive demand where reduced infusion frequency or familiar dosing profiles align better with specific patient lifestyles and clinical objectives. This variance shapes clinical guidelines and payer evaluations differently depending on long-term adherence expectations and safety monitoring commitments.
Examining indication segments, Hemophilia A and Hemophilia B present distinct therapeutic demands based on severity categorizations of mild, moderate, and severe, which influence prophylaxis strategies and episodic intervention patterns. Von Willebrand Disease adds complexity through its Type I, Type II, and Type III subtypes, each requiring tailored dosing algorithms and supportive care models. These clinical distinctions have direct implications for product positioning and evidence generation, as trials and real-world studies must reflect severity- and subtype-specific outcomes to inform guideline adoption.
Formulation differences between liquid and lyophilized powder presentations affect operational workflows at point of care, storage infrastructure, and patient administration capabilities. Hospitals and specialty centers as end users demonstrate divergent procurement processes and clinical expertise, with specialty centers often driving adoption of advanced therapeutics and hospitals emphasizing inventory control and throughput efficiency. Distribution channel dynamics further influence access, where hospital pharmacies, online pharmacies, and retail pharmacies each introduce distinct fulfillment timelines, reimbursement interactions, and patient support touchpoints.
Finally, the uniform route of administration by intravenous infusion concentrates attention on infusion-related safety, venous access management, and opportunities for device-enabled delivery improvements. Across all segmentation axes, manufacturers and providers must align clinical value propositions with operational realities to ensure that product design, commercialization strategies, and support services meet the differentiated needs of each segment.
Interpreting how divergent regulatory, reimbursement, and manufacturing ecosystems across major global regions drive distinct strategic imperatives for market entry and expansion
Regional dynamics fundamentally influence clinical practice, regulatory pathways, manufacturing strategies, and access programs. In the Americas, strong clinical infrastructures, extensive specialist networks, and established reimbursement mechanisms create an environment conducive to rapid adoption of advanced biologics, while procurement sensitivity to cost and payer-driven care models keeps emphasis on evidence of improved outcomes and total cost of care. This region also hosts significant manufacturing and distribution capabilities that support scale and rapid response to demand fluctuations.
Across Europe, the Middle East & Africa, diverse regulatory frameworks and payer heterogeneity present both challenges and opportunities. Western European systems emphasize health technology assessments and robust post-marketing evidence, whereas markets across the Middle East and Africa are characterized by variable procurement capacity and growing investment in specialty care. Manufacturers must therefore adapt pricing, distribution, and access strategies to reflect regional willingness-to-pay, regulatory timelines, and local manufacturing or import considerations.
In Asia-Pacific, rapid clinical adoption in some markets is balanced by disparities in infrastructure and reimbursement across countries. The region demonstrates strong investment in biologics manufacturing capacity and an increasing focus on local clinical trials and regulatory convergence. Patient demographics and evolving specialty care networks make the region strategically important for long-term growth, but success depends on nuanced market entry approaches that integrate local partnerships, regulatory intelligence, and tailored patient support programs.
Evaluating the distinct strategic postures and partnership models companies employ to secure clinical adoption, manufacturing resilience, and payer alignment in coagulation therapies
Competitive behavior among companies in the coagulation factor concentrates space is shaped by differentiated investment priorities across product innovation, manufacturing capacity, and downstream services. Leading biopharmaceutical firms emphasize durable innovation pipelines and expanded evidence generation to support premium positioning, while specialty biologics and niche players focus on formulation advantages, patient support, and targeted clinical education to secure adoption in defined cohorts. Contract manufacturing organizations and regional producers are increasing their strategic relevance by enabling faster local production and greater supply security.
Partnerships and strategic alliances are proving essential tools to accelerate market access and broaden therapeutic portfolios. Licensing agreements, co-development arrangements, and outcomes-based contracts are increasingly used to align incentives between manufacturers, payers, and providers. Within this competitive tapestry, companies that integrate clinical development with operational scale, regulatory expertise, and robust patient-centric services are most likely to maintain commercial momentum. Moreover, companies that invest in manufacturing redundancy and transparent quality systems establish stronger negotiating positions with institutional purchasers and payers.
Actionable strategic and operational recommendations for manufacturers, payers, and providers to strengthen supply resilience, evidence generation, and patient access in coagulation care
Industry leaders should prioritize integrated strategies that combine clinical differentiation with operational resilience and payer-focused evidence. First, investing in manufacturing flexibility and geographically diversified production reduces exposure to import constraints and tariff volatility while enabling faster response to demand spikes. Concurrently, dedicating resources to robust real-world evidence generation and outcomes tracking strengthens reimbursement negotiations and supports value-based contracting.
Second, enhancing patient and provider support through digital adherence tools, infusion training, and care coordination programs improves clinical outcomes and bolsters product positioning. Third, optimize go-to-market models by aligning distribution pathways with end-user needs: hospitals require predictable supply and inventory management solutions, specialty centers demand deep clinical engagement, and pharmacy channels benefit from streamlined fulfillment and patient education. Additionally, pursue strategic collaborations for localized manufacturing, regulatory support, and market access to accelerate entry and reduce time-to-treatment while sharing commercial risk.
Finally, maintain proactive regulatory engagement and scenario planning to anticipate policy shifts, tariff impacts, and reimbursement changes. Establish clear contingency plans and cross-functional task forces to ensure rapid decision-making during disruptions. By executing these coordinated actions, industry leaders can create defensible positions that preserve patient access, support sustainable growth, and deliver measurable clinical and economic value.
Describing the multidisciplinary research approach that integrates expert interviews, regulatory review, and analytical triangulation to underpin strategic conclusions robustly
The research methodology underpinning this analysis integrates qualitative and quantitative approaches to deliver a robust and defensible evidence base. Primary research included structured interviews with clinical experts, procurement leads, manufacturing specialists, and regulatory affairs professionals to capture first-hand perspectives on clinical practice, supply chain resilience, and policy impacts. Secondary research incorporated peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to corroborate themes and capture historical trends.
Analytical techniques included comparative policy analysis, supply chain mapping, and therapeutic segmentation modeling to identify strategic inflection points and operational vulnerabilities. Cross-validation and triangulation were used to reconcile inconsistencies across sources and to ensure conclusions reflect both clinical realities and commercial constraints. Ethical research practices and data provenance standards were observed throughout the process, and limitations were explicitly considered to contextualize findings and guide appropriate application of insights by decision-makers.
Concluding synthesis of clinical progress, operational imperatives, and strategic priorities required to sustain access and value in the coagulation concentrates ecosystem
In summary, the coagulation factor concentrates landscape is evolving under simultaneous pressures of clinical innovation, supply chain complexity, and policy shifts. Recombinant and formulation advances are creating meaningful clinical benefits, but these gains must be supported by resilient manufacturing, targeted evidence programs, and adaptive commercialization models. Tariff changes and regional regulatory variation further underscore the need for strategic flexibility and localized operational planning.
For stakeholders across the value chain, the imperative is clear: align product development, manufacturing strategy, and market access activities around demonstrable patient outcomes and supply continuity. Organizations that couple clinical differentiation with proactive risk management and robust payer engagement will be best positioned to sustain access and drive long-term impact for patients living with bleeding disorders. These conclusions provide a strategic framework for prioritizing investments and tactical initiatives moving forward.
Note: PDF & Excel + Online Access - 1 Year
Providing a clear contextual foundation for current clinical, regulatory, and commercial dynamics shaping coagulation factor concentrates across care settings
Coagulation factor concentrates remain central to the management of inherited bleeding disorders and acquired coagulopathies, shaping care pathways across hospitals and specialty treatment centers. Over the past decade, therapeutic sophistication has increased as recombinant engineering and product formulation advances improved safety profiles and dosing convenience. These clinical improvements occur alongside evolving health system expectations for cost containment, supply reliability, and demonstrable patient outcomes, which together influence purchasing decisions and treatment protocols.
Clinicians and health systems now balance efficacy with practical considerations such as storage, administration logistics, and continuity of supply. Meanwhile, regulatory frameworks are maturing to accommodate novel biologics, accelerated approvals, and post-marketing surveillance demands. As a result, stakeholders from manufacturers to payers and providers must navigate a complex environment where clinical evidence, manufacturing capacity, and health-economic justification intersect. This introduction frames the broader commercial and clinical context for deeper strategic analysis and highlights why a disciplined, evidence-driven response is essential for sustained competitiveness.
Analyzing the multifaceted technological, regulatory, and operational shifts reshaping product development, supply chains, and care pathways in coagulation therapies
The landscape for coagulation factor concentrates is undergoing transformative shifts that are redefining competitive advantage and patient pathways. Recombinant biologics with improved half-life properties have altered treatment cadence and adherence patterns, while formulation innovations such as ready-to-use liquid and stable lyophilized presentations have reduced administration burdens in acute and chronic care settings. Concurrently, digital therapeutics and remote monitoring are beginning to complement infusion programs, enabling more precise dosing and improved safety surveillance.
Supply chain resiliency and manufacturing decentralization are gaining priority as stakeholders seek to mitigate disruption risks and meet localized demand. Regulatory convergence on quality and traceability has increased expectations for post-market evidence generation and cold-chain integrity. Moreover, evolving reimbursement frameworks now place greater emphasis on value-based outcomes, prompting manufacturers to invest in real-world evidence and patient support services. Taken together, these shifts require companies to integrate clinical innovation with operational agility and evidence generation to secure long-term market relevance.
Assessing the broad operational, procurement, and strategic consequences resulting from United States tariff policy changes and their downstream effects on global supply dynamics
The introduction of new tariff measures in the United States in 2025 has created a cascade of operational and strategic responses across global suppliers and domestic purchasers of coagulation factor concentrates. Increased import-related costs have prompted manufacturers to reassess global production footprints and accelerate plans for local manufacturing or contract manufacturing organization partnerships to protect margin and continuity of supply. For institutional buyers, procurement teams are recalibrating tender specifications and supplier qualification criteria to reflect shifting landed costs and to preserve access for vulnerable patient populations.
In response, companies are employing hedging strategies, renegotiating long-term supply agreements, and exploring localized inventory buffers to reduce exposure to tariff volatility. Meanwhile, regulatory and market access teams are prioritized to expedite alternate sourcing approvals and to align labeling and quality documentation across jurisdictions. These adaptations are fostering greater collaboration between commercial, legal, and manufacturing functions within organizations. Importantly, the tariff-driven environment also incentivizes innovation in logistics, including consolidated shipping, optimized cold-chain strategies, and strategic warehousing, all aimed at sustaining patient access while containing operational complexity.
Delivering granular strategic insights across product type, clinical indication, formulation, end user, distribution channels, and administration route to inform targeted commercialization
A nuanced segmentation analysis highlights differentiated commercial and clinical imperatives across product types, indications, formulations, end users, distribution channels, and administration routes. Within product type, plasma-derived offerings continue to play a critical role where established safety records and donor-derived attributes are prioritized, while recombinant products-split between extended half-life and standard half-life variants-drive demand where reduced infusion frequency or familiar dosing profiles align better with specific patient lifestyles and clinical objectives. This variance shapes clinical guidelines and payer evaluations differently depending on long-term adherence expectations and safety monitoring commitments.
Examining indication segments, Hemophilia A and Hemophilia B present distinct therapeutic demands based on severity categorizations of mild, moderate, and severe, which influence prophylaxis strategies and episodic intervention patterns. Von Willebrand Disease adds complexity through its Type I, Type II, and Type III subtypes, each requiring tailored dosing algorithms and supportive care models. These clinical distinctions have direct implications for product positioning and evidence generation, as trials and real-world studies must reflect severity- and subtype-specific outcomes to inform guideline adoption.
Formulation differences between liquid and lyophilized powder presentations affect operational workflows at point of care, storage infrastructure, and patient administration capabilities. Hospitals and specialty centers as end users demonstrate divergent procurement processes and clinical expertise, with specialty centers often driving adoption of advanced therapeutics and hospitals emphasizing inventory control and throughput efficiency. Distribution channel dynamics further influence access, where hospital pharmacies, online pharmacies, and retail pharmacies each introduce distinct fulfillment timelines, reimbursement interactions, and patient support touchpoints.
Finally, the uniform route of administration by intravenous infusion concentrates attention on infusion-related safety, venous access management, and opportunities for device-enabled delivery improvements. Across all segmentation axes, manufacturers and providers must align clinical value propositions with operational realities to ensure that product design, commercialization strategies, and support services meet the differentiated needs of each segment.
Interpreting how divergent regulatory, reimbursement, and manufacturing ecosystems across major global regions drive distinct strategic imperatives for market entry and expansion
Regional dynamics fundamentally influence clinical practice, regulatory pathways, manufacturing strategies, and access programs. In the Americas, strong clinical infrastructures, extensive specialist networks, and established reimbursement mechanisms create an environment conducive to rapid adoption of advanced biologics, while procurement sensitivity to cost and payer-driven care models keeps emphasis on evidence of improved outcomes and total cost of care. This region also hosts significant manufacturing and distribution capabilities that support scale and rapid response to demand fluctuations.
Across Europe, the Middle East & Africa, diverse regulatory frameworks and payer heterogeneity present both challenges and opportunities. Western European systems emphasize health technology assessments and robust post-marketing evidence, whereas markets across the Middle East and Africa are characterized by variable procurement capacity and growing investment in specialty care. Manufacturers must therefore adapt pricing, distribution, and access strategies to reflect regional willingness-to-pay, regulatory timelines, and local manufacturing or import considerations.
In Asia-Pacific, rapid clinical adoption in some markets is balanced by disparities in infrastructure and reimbursement across countries. The region demonstrates strong investment in biologics manufacturing capacity and an increasing focus on local clinical trials and regulatory convergence. Patient demographics and evolving specialty care networks make the region strategically important for long-term growth, but success depends on nuanced market entry approaches that integrate local partnerships, regulatory intelligence, and tailored patient support programs.
Evaluating the distinct strategic postures and partnership models companies employ to secure clinical adoption, manufacturing resilience, and payer alignment in coagulation therapies
Competitive behavior among companies in the coagulation factor concentrates space is shaped by differentiated investment priorities across product innovation, manufacturing capacity, and downstream services. Leading biopharmaceutical firms emphasize durable innovation pipelines and expanded evidence generation to support premium positioning, while specialty biologics and niche players focus on formulation advantages, patient support, and targeted clinical education to secure adoption in defined cohorts. Contract manufacturing organizations and regional producers are increasing their strategic relevance by enabling faster local production and greater supply security.
Partnerships and strategic alliances are proving essential tools to accelerate market access and broaden therapeutic portfolios. Licensing agreements, co-development arrangements, and outcomes-based contracts are increasingly used to align incentives between manufacturers, payers, and providers. Within this competitive tapestry, companies that integrate clinical development with operational scale, regulatory expertise, and robust patient-centric services are most likely to maintain commercial momentum. Moreover, companies that invest in manufacturing redundancy and transparent quality systems establish stronger negotiating positions with institutional purchasers and payers.
Actionable strategic and operational recommendations for manufacturers, payers, and providers to strengthen supply resilience, evidence generation, and patient access in coagulation care
Industry leaders should prioritize integrated strategies that combine clinical differentiation with operational resilience and payer-focused evidence. First, investing in manufacturing flexibility and geographically diversified production reduces exposure to import constraints and tariff volatility while enabling faster response to demand spikes. Concurrently, dedicating resources to robust real-world evidence generation and outcomes tracking strengthens reimbursement negotiations and supports value-based contracting.
Second, enhancing patient and provider support through digital adherence tools, infusion training, and care coordination programs improves clinical outcomes and bolsters product positioning. Third, optimize go-to-market models by aligning distribution pathways with end-user needs: hospitals require predictable supply and inventory management solutions, specialty centers demand deep clinical engagement, and pharmacy channels benefit from streamlined fulfillment and patient education. Additionally, pursue strategic collaborations for localized manufacturing, regulatory support, and market access to accelerate entry and reduce time-to-treatment while sharing commercial risk.
Finally, maintain proactive regulatory engagement and scenario planning to anticipate policy shifts, tariff impacts, and reimbursement changes. Establish clear contingency plans and cross-functional task forces to ensure rapid decision-making during disruptions. By executing these coordinated actions, industry leaders can create defensible positions that preserve patient access, support sustainable growth, and deliver measurable clinical and economic value.
Describing the multidisciplinary research approach that integrates expert interviews, regulatory review, and analytical triangulation to underpin strategic conclusions robustly
The research methodology underpinning this analysis integrates qualitative and quantitative approaches to deliver a robust and defensible evidence base. Primary research included structured interviews with clinical experts, procurement leads, manufacturing specialists, and regulatory affairs professionals to capture first-hand perspectives on clinical practice, supply chain resilience, and policy impacts. Secondary research incorporated peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to corroborate themes and capture historical trends.
Analytical techniques included comparative policy analysis, supply chain mapping, and therapeutic segmentation modeling to identify strategic inflection points and operational vulnerabilities. Cross-validation and triangulation were used to reconcile inconsistencies across sources and to ensure conclusions reflect both clinical realities and commercial constraints. Ethical research practices and data provenance standards were observed throughout the process, and limitations were explicitly considered to contextualize findings and guide appropriate application of insights by decision-makers.
Concluding synthesis of clinical progress, operational imperatives, and strategic priorities required to sustain access and value in the coagulation concentrates ecosystem
In summary, the coagulation factor concentrates landscape is evolving under simultaneous pressures of clinical innovation, supply chain complexity, and policy shifts. Recombinant and formulation advances are creating meaningful clinical benefits, but these gains must be supported by resilient manufacturing, targeted evidence programs, and adaptive commercialization models. Tariff changes and regional regulatory variation further underscore the need for strategic flexibility and localized operational planning.
For stakeholders across the value chain, the imperative is clear: align product development, manufacturing strategy, and market access activities around demonstrable patient outcomes and supply continuity. Organizations that couple clinical differentiation with proactive risk management and robust payer engagement will be best positioned to sustain access and drive long-term impact for patients living with bleeding disorders. These conclusions provide a strategic framework for prioritizing investments and tactical initiatives moving forward.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
196 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Growing adoption of extended half-life factor VIII and IX products to reduce infusion frequency and improve patient adherence
- 5.2. Increased investment in gene therapy trials targeting hemophilia A and B to offer one-time curative treatment opportunities
- 5.3. Emergence of biosimilar factor VIII and IX concentrates challenging established branded products on pricing and market access
- 5.4. Integration of pharmacokinetic-guided personalized dosing platforms to optimize coagulation factor concentrate prophylaxis regimens
- 5.5. Development of subcutaneous and nonintravenous factor concentrate formulations aimed at improving patient convenience and quality of life
- 5.6. Expansion of plasma collection networks and digital supply chain solutions to mitigate global shortages of source material
- 5.7. Application of real-world evidence and registry data to demonstrate long-term safety and efficacy of novel coagulation therapies
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Coagulation Factor Concentrates Market, by Product Type
- 8.1. Plasma Derived
- 8.2. Recombinant
- 8.2.1. Extended Half Life
- 8.2.2. Standard Half Life
- 9. Coagulation Factor Concentrates Market, by Indication
- 9.1. Hemophilia A
- 9.1.1. Mild
- 9.1.2. Moderate
- 9.1.3. Severe
- 9.2. Hemophilia B
- 9.2.1. Mild
- 9.2.2. Moderate
- 9.2.3. Severe
- 9.3. Von Willebrand Disease
- 9.3.1. Type I
- 9.3.2. Type II
- 9.3.3. Type III
- 10. Coagulation Factor Concentrates Market, by Formulation
- 10.1. Liquid
- 10.2. Lyophilized Powder
- 11. Coagulation Factor Concentrates Market, by End User
- 11.1. Hospitals
- 11.2. Specialty Centers
- 12. Coagulation Factor Concentrates Market, by Distribution Channel
- 12.1. Hospital Pharmacies
- 12.2. Online Pharmacies
- 12.3. Retail Pharmacies
- 13. Coagulation Factor Concentrates Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Coagulation Factor Concentrates Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Coagulation Factor Concentrates Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Bayer AG
- 16.3.2. Bio Products Laboratory Limited
- 16.3.3. BIOGEN INC.
- 16.3.4. Biotest AG.
- 16.3.5. Cerus Corporation
- 16.3.6. CSL Limited
- 16.3.7. Emergent BioSolutions Inc.
- 16.3.8. Grifols, S.A.
- 16.3.9. Kedrion S.p.A
- 16.3.10. LFB USA
- 16.3.11. Medscape Network
- 16.3.12. Novo Nordisk A/S
- 16.3.13. Octapharma AG
- 16.3.14. Pfizer Inc.
- 16.3.15. Sanofi S.A.
- 16.3.16. Takeda Pharmaceutical Company Limited
- 16.3.17. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
